

Update on the diagnosis and treatment of neuromyeliti
Neuromyelitis Optica Study Group (NEMOS)

Journal of Neurology

261, 1-16

DOI: [10.1007/s00415-013-7169-7](https://doi.org/10.1007/s00415-013-7169-7)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Crescentic glomerulonephritis in a patient with neuromyelitis optica (Devic's syndrome). Case Reports in Internal Medicine, 2014, 2, .	0.0	0
3	Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. Journal of Neuroinflammation, 2014, 11, 129.	3.1	24
4	Interferon- β -related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. BMC Neurology, 2014, 14, 247.	0.8	21
5	Relapsing inappropriate antidiuretic hormone secretion in an anti-aquaporin-4 antibody positive paediatric patient. Multiple Sclerosis Journal, 2014, 20, 1404-1406.	1.4	4
7	NMO spectrum disorders: how wide is the spectrum?. Multiple Sclerosis Journal, 2014, 20, 1417-1419.	1.4	2
8	â€œSpinal amaurosisâ€™ (1841). On the early contribution of Edward Hocken to the concept of neuromyelitis optica. Journal of Neurology, 2014, 261, 400-404.	1.8	8
9	B cells in MS and NMO: pathogenesis and therapy. Seminars in Immunopathology, 2014, 36, 339-350.	2.8	72
10	Continuing fingolimod after development of macular edema: A case report. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e13.	3.1	18
11	Recent advances in the neuroimmunology of cell-surface CNS autoantibody syndromes, Alzheimer's disease, traumatic brain injury and schizophrenia. Journal of Neurology, 2014, 261, 2037-2042.	1.8	7
12	Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nature Reviews Neurology, 2014, 10, 493-506.	4.9	220
13	Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurology, The, 2014, 13, 936-948.	4.9	124
15	Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report. Journal of Medical Case Reports, 2014, 8, 155.	0.4	16
16	Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clinical and Experimental Immunology, 2014, 176, 149-164.	1.1	277
17	Systemic Lupus Erythematosus (SLE) Complicated by Neuromyelitis Optica (NMO â€œ Devic's Disease): Clinic-Pathological Report and Review of the Literature. Clinical Medicine Insights: Case Reports, 2014, 7, CCRep.S15177.	0.3	23
18	Paraneoplastic neuromyelitis optica spectrum disorder manifesting as intractable nausea and acute cerebellar ataxia associated with lung adenocarcinoma. Neurology and Clinical Neuroscience, 2015, 3, 223-225.	0.2	2
19	Prolonged effect of temporary rituximab therapy in neuromyelitis optica â€œ A case study. Postepy Psychiatrii I Neurologii, 2015, 24, 239-243.	0.2	1
20	Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis. Journal of Neuroinflammation, 2015, 12, 196.	3.1	27
21	Ultrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease management. EPMA Journal, 2015, 6, 16.	3.3	36

#	ARTICLE	IF	CITATIONS
22	Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositive patients in a Chinese population. <i>BMC Neurology</i> , 2015, 15, 160.	0.8	31
23	The intrathecal, polyspecific antiviral immune response in neurosarcoidosis, acute disseminated encephalomyelitis and autoimmune encephalitis compared to multiple sclerosis in a tertiary hospital cohort. <i>Fluids and Barriers of the CNS</i> , 2015, 12, 27.	2.4	31
24	Methotrexate is effective for the treatment of neuromyelitis optica spectrum disorders in Asian patients. <i>Clinical and Experimental Neuroimmunology</i> , 2015, 6, 149-153.	0.5	2
25	MRI in the Evaluation of Acute Visual Syndromes. <i>Topics in Magnetic Resonance Imaging</i> , 2015, 24, 309-324.	0.7	6
26	Hypoxemia, Sleep Disturbances, and Depression Correlated with Fatigue in Neuromyelitis Optica Spectrum Disorder. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 599-606.	1.9	39
27	Eculizumab, Neuromyelitis Optica, and Tuberculosis: We Live An Era of Challenging Combinations. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 914-915.	1.9	2
28	The profile of patients followed at the Neuroimmunology Clinic at UNIFESP: 20 years analysis. <i>Arquivos De Neuro-Psiquiatria</i> , 2015, 73, 304-308.	0.3	8
29	Neuromyelitis optica and myasthenia gravis in a young Nigerian girl: Figure 1. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014207362.	0.2	6
30	The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis: A Clinical Proteome Study. <i>PLoS ONE</i> , 2015, 10, e0139659.	1.1	15
31	A Case Study of Intractable Vomiting with Final Diagnosis of Neuromyelitis Optica. <i>Case Reports in Pediatrics</i> , 2015, 2015, 1-7.	0.2	4
32	The Diagnosis and Treatment of Optic Neuritis. <i>Deutsches Ärzteblatt International</i> , 2015, 112, 616-25; quiz 626.	0.6	72
33	Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review. <i>Journal of the Neurological Sciences</i> , 2015, 355, 7-17.	0.3	49
34	Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. <i>JAMA Neurology</i> , 2015, 72, 756.	4.5	206
35	Pathophysiologisch ansetzende Therapie. , 2015, , 267-359.		0
36	Neuro-Ophthalmology Annual Review. <i>Asia-Pacific Journal of Ophthalmology</i> , 2015, 4, 307-315.	1.3	0
37	Pushing the boundaries of neuromyelitis optica. <i>Neurology</i> , 2015, 85, 118-119.	1.5	14
38	Enfermedades no degenerativas de la médula espinal. <i>Medicine</i> , 2015, 11, 4687-4697.	0.0	1
39	Tumefactive demyelination of the spinal cord: a case report. <i>Spinal Cord</i> , 2015, 53, 877-880.	0.9	7

#	ARTICLE	IF	CITATIONS
40	Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 803-824.	1.4	30
41	Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. <i>Journal of Neuroimmunology</i> , 2015, 282, 92-96.	1.1	40
42	Differential patterns of spinal cord and brain atrophy in NMO and MS. <i>Neurology</i> , 2015, 84, 1465-1472.	1.5	70
43	Longitudinally extensive transverse myelitis in neuromyelitis optica: a prospective study of 13 Caucasian patients and literature review. <i>Acta Neurologica Belgica</i> , 2015, 115, 635-642.	0.5	7
46	Hereditary diffuse leukoencephalopathy with spheroids (HDLS) with a novel CSF1R mutation and spinal cord involvement. <i>Journal of the Neurological Sciences</i> , 2015, 358, 515-517.	0.3	12
47	Gamma-aminobutyric acid receptor agonists, aquaporin-4, and neuromyelitis optica: a potential link. <i>Medical Hypotheses</i> , 2015, 85, 628-630.	0.8	6
48	Neuromyelitis optica spectrum disorder and multiple sclerosis: Differentiation by a multimodal approach. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 515-520.	0.9	10
50	Devic's disease before Devic: Bilateral optic neuritis and simultaneous myelitis in a young woman (1874). <i>Journal of the Neurological Sciences</i> , 2015, 358, 419-421.	0.3	6
51	A placebo controlled trial for an NMO relapse prevention treatment: Ethical considerations. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 580-584.	0.9	4
52	Anti-aquaporin 4 antibody-positive acute disseminated encephalomyelitis. <i>Brain and Development</i> , 2015, 37, 339-343.	0.6	5
53	Intractable Hiccups and Nausea as a Principal Symptom of Neuromyelitis Optica in a Patient with a Prior History of Miller-Fisher Syndrome. <i>Journal of General and Family Medicine</i> , 2016, 17, 99-104.	0.3	0
54	Atypical inflammatory demyelinating syndromes of the CNS. <i>Lancet Neurology</i> , The, 2016, 15, 967-981.	4.9	121
55	Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e208.	3.1	9
56	Plasma exchange therapy for a severe relapse of Devic's disease in a pregnant woman: A case report and concise review. <i>Clinical Neurology and Neurosurgery</i> , 2016, 148, 88-90.	0.6	12
57	Neuromyelitis Optica Spectrum Disorder: Disease Course and Long-Term Visual Outcome. <i>Journal of Neuro-Ophthalmology</i> , 2016, 36, 356-362.	0.4	12
59	Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. <i>Neurology</i> , 2016, 86, 1683-1691.	1.5	149
60	Neuromyelitis optica does not impact periventricular venous density versus healthy controls: a 7.0-Tesla MRI clinical study. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2016, 29, 535-541.	1.1	9
61	Optic neuritis with positive HLA-B27: Characteristic phenotype in the Chinese population. <i>Journal of the Neurological Sciences</i> , 2016, 362, 100-105.	0.3	7

#	ARTICLE	IF	CITATIONS
62	Current and future immunotherapy targets in autoimmune neurology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 511-536.	1.0	4
63	Restoring immune tolerance in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e277.	3.1	39
64	High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporinâ€4 competing with the neuromyelitis optica autoantibody, NMOâ€IgG. British Journal of Pharmacology, 2016, 173, 103-114.	2.7	10
65	Pediatric transverse myelitis. Neurology, 2016, 87, S46-52.	1.5	92
66	Neuromyelitis optica spectrum disorders in children and adolescents. Neurology, 2016, 87, S59-66.	1.5	78
67	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. Journal of Neuroinflammation, 2016, 13, 280.	3.1	686
68	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. Journal of Neuroinflammation, 2016, 13, 282.	3.1	217
69	Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO). Journal of Neuroinflammation, 2016, 13, 179.	3.1	38
70	Other noninfectious inflammatory disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 135, 425-446.	1.0	8
71	Neuromyelitis Optica (Devicâ€™s Syndrome): an Appraisal. Current Rheumatology Reports, 2016, 18, 54.	2.1	13
72	Treatment of primary SjÃ¶rgren syndrome. Nature Reviews Rheumatology, 2016, 12, 456-471.	3.5	137
73	Multiple Sclerosis and Neurodegenerative Diseases. , 2016, , 63-84.		9
74	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. Journal of Neuroinflammation, 2016, 13, 281.	3.1	202
75	Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e286.	3.1	85
76	Inpatient Multidisciplinary Rehabilitation Intervention Outcomes for Neuromyelitis Optica Spectrum Disorder: A Retrospective Observational Study. Progress in Rehabilitation Medicine, 2016, 1, n/a.	0.3	1
77	The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica. BMC Neurology, 2016, 16, 203.	0.8	16
79	Placebo-controlled study in neuromyelitis opticaâ€™Ethical and design considerations. Multiple Sclerosis Journal, 2016, 22, 862-872.	1.4	63
80	Immunoadsorption in patients with neuromyelitis optica spectrum disorder. Therapeutic Advances in Neurological Disorders, 2016, 9, 281-286.	1.5	29

#	ARTICLE	IF	CITATIONS
81	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016, 79, 206-216.	2.8	315
82	A window to beyond the orbit: the value of optical coherence tomography in non-ocular disease. <i>Acta Ophthalmologica</i> , 2016, 94, 533-539.	0.6	10
83	A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis Optica. <i>Journal of Proteome Research</i> , 2016, 15, 659-666.	1.8	45
84	Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e188.	3.1	60
85	Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. <i>Journal of Neurology</i> , 2016, 263, 575-582.	1.8	53
86	Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e204.	3.1	53
87	Fingolimod in the treatment of relapsing-remitting multiple sclerosis: long-term experience and an update on the clinical evidence. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 130-147.	1.5	58
88	Investigation-Directed Approach to Inflammatory Optic Neuropathies. <i>Seminars in Ophthalmology</i> , 2016, 31, 117-130.	0.8	12
89	Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. <i>Autoimmunity Reviews</i> , 2016, 15, 307-324.	2.5	229
90	Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID). <i>Journal of NeuroImmune Pharmacology</i> , 2016, 11, 1-8.	2.1	33
91	Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. <i>Neurotherapeutics</i> , 2016, 13, 70-83.	2.1	90
92	Brainstem and limbic encephalitis with paraneoplastic neuromyelitis optica. <i>Journal of Clinical Neuroscience</i> , 2016, 23, 159-161.	0.8	14
93	Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity. <i>Neurotherapeutics</i> , 2016, 13, 163-178.	2.1	17
94	What do we know about brain contrast enhancement patterns in neuromyelitis optica?. <i>Clinical Imaging</i> , 2016, 40, 573-580.	0.8	25
95	Neuromyelitis optica spectrum disorders may be misdiagnosed as Wernicke's encephalopathy. <i>International Journal of Neuroscience</i> , 2016, 126, 922-927.	0.8	9
96	Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 470-482.	1.4	284
97	Therapeutic complement inhibition: a promising approach for treatment of neuroimmunological diseases. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 579-591.	1.4	13
98	The clinical characteristics of AQP4 antibody positive NMO/SD in a large cohort of Chinese Han patients. <i>Journal of Neuroimmunology</i> , 2017, 302, 49-55.	1.1	29

#	ARTICLE	IF	CITATIONS
99	MOG-antibody associated demyelinating disease of the CNS: A clinical and pathological study in Chinese Han patients. <i>Journal of Neuroimmunology</i> , 2017, 305, 19-28.	1.1	84
101	Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study. <i>Acta Neurologica Belgica</i> , 2017, 117, 695-702.	0.5	42
102	Failure of alemtuzumab therapy to control MOG encephalomyelitis. <i>Neurology</i> , 2017, 89, 207-209.	1.5	27
103	NMO Spectrum Disorders. <i>Neurology International Open</i> , 2017, 01, E36-E47.	0.4	3
104	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 639-647.	0.9	123
105	Devic's disease before Devic: On the contribution of Friedrich Albin Schanz (1863-1923). <i>Journal of the Neurological Sciences</i> , 2017, 379, 99-102.	0.3	6
106	Neuromyelitis optica and neuromyelitis optica spectrum disorders. <i>Current Opinion in Neurology</i> , 2017, 30, 208-215.	1.8	38
107	What's new in neuromyelitis optica? A short review for the clinical neurologist. <i>Journal of Neurology</i> , 2017, 264, 2330-2344.	1.8	26
108	Intractable Nausea Due to the Area Postrema Syndrome of Neuromyelitis Optica: An Uncommon Cause of a Common Symptom. <i>Journal of Emergency Medicine</i> , 2017, 53, e73-e76.	0.3	4
109	Neurological Complications of Sjögren's Syndrome: Diagnosis and Management. <i>Current Treatment Options in Rheumatology</i> , 2017, 3, 275-288.	0.6	45
110	Fatigue as a symptom or comorbidity of neurological diseases. <i>Nature Reviews Neurology</i> , 2017, 13, 662-675.	4.9	270
113	Cortical blindness and not optic neuritis as a cause of vision loss in a Sjögren's syndrome (SS) patient with the neuromyelitis optica spectrum disorder (NMOSD). <i>Medicine (United States)</i> , 2017, 96, e7454.	0.4	9
114	Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. <i>Journal of Neurology</i> , 2017, 264, 2003-2009.	1.8	146
115	Neuromyelitis optica spectrum disorders: Emerging therapies. <i>Clinical and Experimental Neuroimmunology</i> , 2017, 8, 107-116.	0.5	10
116	Neurological safety of fingolimod: An updated review. <i>Clinical and Experimental Neuroimmunology</i> , 2017, 8, 233-243.	0.5	40
117	Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system. <i>EPMA Journal</i> , 2017, 8, 279-294.	3.3	35
118	Management of Immune-Mediated Paraneoplastic Neurological Disorders. <i>Neurology International Open</i> , 2017, 01, E264-E274.	0.4	3
120	LC-MS/MS Analysis of Erythrocyte Thiopurine Nucleotides and Their Association With Genetic Variants in Patients With Neuromyelitis Optica Spectrum Disorders Taking Azathioprine. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 5-12.	1.0	9

#	ARTICLE	IF	CITATIONS
121	Myelitis in systemic lupus erythematosus. <i>Journal of Clinical Neuroscience</i> , 2017, 44, 18-22.	0.8	20
122	Combined brain and anterior visual pathwaysâ€™ MRIs assist in early identification of neuromyelitis optica spectrum disorder at onset of optic neuritis. <i>Acta Neurologica Belgica</i> , 2017, 117, 67-74.	0.5	9
123	Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1092-1103.	1.4	60
124	Development of a patientâ€™centred conceptual framework of healthâ€™related quality of life in neuromyelitis optica: a qualitative study. <i>Health Expectations</i> , 2017, 20, 47-58.	1.1	15
125	Multifrequency magnetic resonance elastography of the brain reveals tissue degeneration in neuromyelitis optica spectrum disorder. <i>European Radiology</i> , 2017, 27, 2206-2215.	2.3	16
126	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1377-1384.	1.4	89
127	Diagnosis of multiple sclerosis: progress and challenges. <i>Lancet, The</i> , 2017, 389, 1336-1346.	6.3	441
131	The Role of Brain-Reactive Autoantibodies in Brain Pathology and Cognitive Impairment. <i>Frontiers in Immunology</i> , 2017, 8, 1101.	2.2	42
132	Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis. <i>Journal of Neuroinflammation</i> , 2017, 14, 171.	3.1	34
133	Comprehensive analysis of patients with neuromyelitis optica spectrum disorder (NMOSD) combined with chronic hepatitis B (CHB) infection and seropositive for anti-aquaporin-4 antibody. <i>Bosnian Journal of Basic Medical Sciences</i> , 2017, 18, 35-42.	0.6	5
134	Investigational drugs in development to prevent neuromyelitis optica relapses. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 265-271.	1.9	40
135	Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy. <i>EPMA Journal</i> , 2018, 9, 21-33.	3.3	75
136	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. <i>Nature Reviews Neurology</i> , 2018, 14, 199-213.	4.9	157
137	Clinical commentary on â€™Two cases of anaphylactic shock by methylprednisolone in neuromyelitis opticaâ€™. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1516-1517.	1.4	0
138	Recent developments in interferon-based therapies for multiple sclerosis. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 665-680.	1.4	21
139	Neuroimmunological Registries in Germany. <i>Neurology International Open</i> , 2018, 02, E25-E39.	0.4	9
140	A Rare Presentation of Neuromyelitis Optica Spectrum Disorders. <i>Clinical Medicine Insights: Case Reports</i> , 2018, 11, 117954761775268.	0.3	1
142	Clinical implications of myelin regeneration in the central nervous system. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 111-123.	1.4	4

#	ARTICLE	IF	CITATIONS
143	Pediatric Neuromyelitis Optica Spectrum Disorders. Current Treatment Options in Neurology, 2018, 20, 19.	0.7	32
144	A woman with intractable nausea and vomiting. BMJ: British Medical Journal, 2018, 361, k1082.	2.4	0
145	Membrane-based therapeutic plasma exchange (mTPE): Technical and clinical experience. Journal of Clinical Apheresis, 2018, 33, 38-45.	0.7	21
146	B-cells as therapeutic targets in neuro-inflammatory diseases. Clinical Immunology, 2018, 186, 51-53.	1.4	6
147	Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2018, 24, 1737-1742.	1.4	41
148	Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 127-137.	0.9	422
149	Development of Neuromyelitis Optica Spectrum Disorder and Spinal Arachnoid Cysts in a Patient With Intractable Epilepsy. Journal of Osteopathic Medicine, 2018, 118, 119-123.	0.4	0
150	SLE presenting as demyelinating autoimmune visual loss. BMJ Case Reports, 2018, 2018, bcr-2017-222158.	0.2	1
151	Ozanimod for the treatment of relapsing remitting multiple sclerosis. Expert Opinion on Pharmacotherapy, 2018, 19, 2073-2086.	0.9	34
154	Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. Frontiers in Neurology, 2018, 9, 888.	1.1	194
155	Epidemiología de la neuromielitis óptica en Costa Rica: un análisis multicéntrico. Neurologia Argentina, 2018, 10, 185-193.	0.1	2
156	Neuro-Immune Hemostasis: Homeostasis and Diseases in the Central Nervous System. Frontiers in Cellular Neuroscience, 2018, 12, 459.	1.8	98
159	Detection of aquaporin-4 antibodies for patients with CNS inflammatory demyelinating diseases other than typical MS in Lithuania. Brain and Behavior, 2018, 8, e01129.	1.0	5
160	The first Japanese report on neuromyelitis optica rediscovered: acute bilateral blindness, tetraparesis and respiratory insufficiency in a 35-year-old man (1891). Journal of the Neurological Sciences, 2018, 395, 121-125.	0.3	4
161	Apheresis therapies for NMOSD attacks. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e504.	3.1	173
162	Treatment strategies for neuromyelitis optica. Tzu Chi Medical Journal, 2018, 30, 204.	0.4	3
163	Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies. EPMA Journal, 2018, 9, 249-256.	3.3	31
164	Resilience and depression/anxiety symptoms in multiple sclerosis and neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2018, 25, 309-315.	0.9	32

#	ARTICLE	IF	CITATIONS
166	Combination Treatment of C16 Peptide and Angiotensin-1 Alleviates Neuromyelitis Optica in an Experimental Model. <i>Mediators of Inflammation</i> , 2018, 2018, 1-14.	1.4	5
167	Multiple Sklerose und andere autoimmune ZNS-Erkrankungen. , 2018, , 1-103.		0
168	Azathioprine-induced pellagra in neuromyelitis optica: A case report and review of literature. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 104-107.	0.9	8
169	Neurological Disease in Lupus: Toward a Personalized Medicine Approach. <i>Frontiers in Immunology</i> , 2018, 9, 1146.	2.2	36
170	Cerebral Blood Flow Changes in Multiple Sclerosis and Neuromyelitis Optica and Their Correlations With Clinical Disability. <i>Frontiers in Neurology</i> , 2018, 9, 305.	1.1	13
171	Emerging Cellular and Molecular Strategies for Enhancing Central Nervous System (CNS) Remyelination. <i>Brain Sciences</i> , 2018, 8, 111.	1.1	27
172	BalÃ³n's concentric sclerosis is immunologically distinct from multiple sclerosis: results from retrospective analysis of almost 150 lumbar punctures. <i>Journal of Neuroinflammation</i> , 2018, 15, 22.	3.1	32
173	Neuromyelitis Optica Spectrum Disorders. , 2018, , 313-335.		1
174	Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731879119.	0.5	39
175	Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641877497.	1.5	24
177	Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders. <i>Neurology and Therapy</i> , 2018, 7, 373-383.	1.4	31
178	Treating neuromyelitis optica with azathioprine: 20-year clinical practice. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1150-1161.	1.4	27
179	Nystagmus and diplopia in a patient with positive aquaporin-4 antibody. <i>Canadian Journal of Ophthalmology</i> , 2019, 54, e66-e69.	0.4	2
180	Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 246-252.	0.9	45
181	14th EUNOS Congress. <i>Neuro-Ophthalmology</i> , 2019, 43, 1-221.	0.4	2
182	Controversies in the management of neuromyelitis optica spectrum disorder. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1127-1133.	1.4	8
183	Neuromyelitis optica spectrum disorder with radiological manifestation of multiple sclerosis in the first brain MRI: a case report. <i>Future Neurology</i> , 2019, 14, FNL15.	0.9	0
184	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 134.	3.1	115

#	ARTICLE	IF	CITATIONS
185	Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e583.	3.1	33
186	Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101430.	0.9	23
187	EMR-integrated minimal core dataset for routine health care and multiple research settings: A case study for neuroinflammatory demyelinating diseases. <i>PLoS ONE</i> , 2019, 14, e0223886.	1.1	10
188	Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis. <i>Lupus</i> , 2019, 28, 1656-1662.	0.8	16
190	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOMentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet, The</i> , 2019, 394, 1352-1363.	6.3	433
191	Immunoadsorption or plasma exchange in steroidâ€refractory multiple sclerosis and neuromyelitis optica. <i>Journal of Clinical Apheresis</i> , 2019, 34, 381-391.	0.7	36
192	Aquaporin-4 Water Channel in the Brain and Its Implication for Health and Disease. <i>Cells</i> , 2019, 8, 90.	1.8	144
193	Visual impairment in neuromyelitis optica spectrum disorders (NMOSD). <i>Journal of Chemical Neuroanatomy</i> , 2019, 97, 66-70.	1.0	6
194	Neuromyelitis optica testing and treatment: Availability and affordability in 60 countries. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 44-50.	0.9	25
195	Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes. <i>Biomedicines</i> , 2019, 7, 42.	1.4	90
196	Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 34, 77-82.	0.9	7
197	Cognitive Impairment in Neuromyelitis Optica Spectrum Disorders: A Review of Clinical and Neuroradiological Features. <i>Frontiers in Neurology</i> , 2019, 10, 608.	1.1	42
198	Epidemiology of neuromyelitis optica spectrum disorder in Denmark (1998â€“2008, 2007â€“2014). <i>Brain and Behavior</i> , 2019, 9, e01338.	1.0	12
199	Clinical Features of Diffuse Leptomeningeal Glioneuronal Tumor with Rapid Blindness Misdiagnosed as NMOSD and Literature Review. <i>SN Comprehensive Clinical Medicine</i> , 2019, 1, 434-441.	0.3	4
200	Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731984846.	0.5	10
201	Clinical Approach to Pediatric Transverse Myelitis, Neuromyelitis Optica Spectrum Disorder and Acute Flaccid Myelitis. <i>Children</i> , 2019, 6, 70.	0.6	12
202	Glial cells as therapeutic targets in progressive multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 481-494.	1.4	10
203	Expression of OX40 Gene and its Serum Levels in Neuromyelitis Optica Patients. <i>Biomolecular Concepts</i> , 2019, 10, 62-67.	1.0	1

#	ARTICLE	IF	CITATIONS
204	Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. <i>Journal of Neuroimmunology</i> , 2019, 332, 126-134.	1.1	14
205	Sjogren's syndrome: An update on disease pathogenesis, clinical manifestations and treatment. <i>Clinical Immunology</i> , 2019, 203, 81-121.	1.4	119
206	Seronegative neuromyelitis optica spectrum disorder: severe polysymptomatic presentation with successful treatment response. <i>BMJ Case Reports</i> , 2019, 12, e228553.	0.2	1
207	Myelinoclastic diffuse sclerosis (Schilder's disease) is immunologically distinct from multiple sclerosis: results from retrospective analysis of 92 lumbar punctures. <i>Journal of Neuroinflammation</i> , 2019, 16, 51.	3.1	16
208	Quantitative 7T MRI does not detect occult brain damage in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e541.	3.1	15
209	Clinical, neuroimaging and therapeutic response in AQP4-positive NMO patients from India. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, 85-93.	0.9	17
210	Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis. <i>Current Neurology and Neuroscience Reports</i> , 2019, 19, 100.	2.0	45
211	Retinal correlates of neurological disorders. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231988220.	1.1	36
212	Neuromyelitis Optica: Review and Utility of Testing Aquaporin-4 Antibody in Typical Optic Neuritis. <i>Asia-Pacific Journal of Ophthalmology</i> , 2019, 7, 229-234.	1.3	7
213	Do Myelin Oligodendrocyte Glycoprotein Antibodies Represent a Distinct Syndrome?. <i>Journal of Neuro-Ophthalmology</i> , 2019, 39, 416-423.	0.4	10
215	Novel uses of retinal imaging with optical coherence tomography in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 31-43.	1.4	44
216	Tocilizumab in MOG-antibody spectrum disorder: a case report. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 312-314.	0.9	24
217	Blockade of IL-6 signaling in neuromyelitis optica. <i>Neurochemistry International</i> , 2019, 130, 104315.	1.9	34
218	Sex differences in autoimmune disorders of the central nervous system. <i>Seminars in Immunopathology</i> , 2019, 41, 177-188.	2.8	74
219	Clinical Characteristics of Anti-aquaporin 4 Antibody Positive Optic Neuritis in Japan. <i>Neuro-Ophthalmology</i> , 2019, 43, 71-80.	0.4	8
220	Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 412-418.	0.9	101
221	Neuromyelitis Optica Spectrum Disorder in a Patient With Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 2019, 25, e38-e40.	0.5	0
222	Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 199-218.	1.8	33

#	ARTICLE	IF	CITATIONS
223	HA280 immunoadsorption, an alternative treatment for neuromyelitis optica spectrum disorders?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101480.	0.9	2
224	Autoimmune and Autoantibody-Associated Encephalomyelopathies. , 2020, , 1067-1114.		1
225	Therapeutic Plasma Exchange in Neuromyelitis Optica Spectrum Disorders and Related Disorders in Resourceâ€limited Settings: Outcomes in a Multiethnic Singleâ€Center Population. <i>Therapeutic Apheresis and Dialysis</i> , 2020, 24, 312-323.	0.4	6
226	Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101920.	0.9	35
227	A study on patients with neuromyelitis optica spectrum disorder from Eastern India. <i>Neurology Psychiatry and Brain Research</i> , 2020, 35, 22-28.	2.0	6
228	MIF -173G/C polymorphism is associated with NMO disease severity. <i>Journal of Neuroimmunology</i> , 2020, 339, 577120.	1.1	2
229	Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	34
230	Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101907.	0.9	9
231	Efficacy and safety of azathioprine for neuromyelitis optica spectrum disorders: A meta-analysis of real-world studies. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102484.	0.9	12
232	Neuromyelitis optica. <i>Nature Reviews Disease Primers</i> , 2020, 6, 85.	18.1	232
233	Sequential intermittent therapeutic plasma exchange: A possible induction and maintenance therapy in the management of adult patients with neuromyelitis optica spectrum disorder. <i>Therapeutic Apheresis and Dialysis</i> , 2020, 25, 513-532.	0.4	5
234	Central Sleep Apnea Syndrome Can Complicate Neuromyelitis Optica Spectrum Disorder: A Case Report. <i>Frontiers in Pediatrics</i> , 2020, 8, 547474.	0.9	5
235	NMOSD acute attack: Understanding, treatment and innovative treatment prospect. <i>Journal of Neuroimmunology</i> , 2020, 348, 577387.	1.1	22
236	Neuromyelitis optica practice and prescribing changes in the setting of Covid19: A survey of neurologists. <i>Journal of Neuroimmunology</i> , 2020, 346, 577320.	1.1	3
237	Safety and efficacy of mycophenolate mofetil in treating neuromyelitis optica spectrum disorders: a protocol for systematic review and meta-analysis. <i>BMJ Open</i> , 2020, 10, e040371.	0.8	2
238	Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders. <i>Annals of Pharmacotherapy</i> , 2021, 55, 1167-1171.	0.9	4
239	Predictive Factors of Resistance to High-Dose Steroids Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Neurology</i> , 2020, 11, 585471.	1.1	6
240	Espectro de neuromielitis Ã³ptica: Â¿seropositivo para la anticuaporina es una entidad diferente de los pacientes que son seronegativos? Una perspectiva de Colombia. <i>NeurologÃ­a</i> , 2023, 38, 504-510.	0.3	1

#	ARTICLE	IF	CITATIONS
241	Eculizumab in the treatment of neuromyelitis optica spectrum disorder. <i>Immunotherapy</i> , 2020, 12, 1053-1066.	1.0	7
242	Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102428.	0.9	42
243	Emerging drugs for the treatment of neuromyelitis optica. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 285-297.	1.0	14
244	Differential Effects of MS Therapeutics on B Cellsâ€™ Implications for Their Use and Failure in AQP4-Positive NMOSD Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5021.	1.8	20
245	Native American ancestry significantly contributes to neuromyelitis optica susceptibility in the admixed Mexican population. <i>Scientific Reports</i> , 2020, 10, 13706.	1.6	18
246	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. <i>Journal of Neuroinflammation</i> , 2020, 17, 262.	3.1	44
247	Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery. <i>Metabolites</i> , 2020, 10, 374.	1.3	7
248	Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD. <i>Frontiers in Neurology</i> , 2020, 11, 932.	1.1	29
249	Vision improvement in severe acute isolated optic neuritis after plasma exchange treatment in Chinese population: a prospective case series study. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642094797.	1.5	8
250	Gender issues of antibody-mediated diseases in neurology: (NMOSD/autoimmune encephalitis/MG). <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642094980.	1.5	23
251	Autologous hematopoietic stem-cell transplantation in neurological disorders: current approach and future directions. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1299-1313.	1.4	7
252	Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2608.	1.0	3
253	<p>Prognostic Factors for Visual Outcomes Following the First Episode of NMOSD-Related Optic Neuritis in Affected Eyes</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 4271-4278.	0.9	9
254	Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. <i>Frontiers in Neurology</i> , 2020, 11, 778.	1.1	37
255	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). <i>BMJ Open</i> , 2020, 10, e035397.	0.8	10
256	Neuromyelitis optica spectrum disorder and active tuberculosis. <i>BMJ Case Reports</i> , 2020, 13, e231524.	0.2	6
257	Spinal Cord Involvement in MS and Other Demyelinating Diseases. <i>Biomedicines</i> , 2020, 8, 130.	1.4	9
258	The 2015 IPND Criteria Increases the Yield in Diagnosis of Neuromyelitis Optica Spectrum Disorder in Thai Patients Compared to the 2006 Diagnostic Criteria. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102218.	0.9	7

#	ARTICLE	IF	CITATIONS
259	Optic neuropathy: A 15-year retrospective observational study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102337.	0.9	4
260	Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. <i>Frontiers in Neurology</i> , 2020, 11, 450.	1.1	29
261	Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. <i>Neurology</i> , 2020, 95, e111-e120.	1.5	140
262	Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder. <i>Clinical Neurology and Neurosurgery</i> , 2020, 196, 106007.	0.6	3
263	Epidemiology of Pediatric NMOSD in Germany and Austria. <i>Frontiers in Neurology</i> , 2020, 11, 415.	1.1	10
264	Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2020, 19, 298-306.	4.9	218
265	Old and new breakthroughs in neuromyelitis optica. <i>Lancet Neurology</i> , The, 2020, 19, 280-281.	4.9	10
267	Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1061-1072.	1.4	15
268	The Detection of Retina Microvascular Density in Subclinical Aquaporin-4 Antibody Seropositive Neuromyelitis Optica Spectrum Disorders. <i>Frontiers in Neurology</i> , 2020, 11, 35.	1.1	26
269	Autoantibody-mediated neurological diseases. <i>Medicine</i> , 2020, 48, 534-540.	0.2	0
270	Urinary Symptoms and Bladder Dysfunction in Patients with Neuromyelitis Optica Spectrum Disorders: Evaluation with Urodynamics and Management. <i>Journal of Neurosciences in Rural Practice</i> , 2020, 11, 245-249.	0.3	7
271	Clinical features of transverse myelitis associated with systemic lupus erythematosus. <i>Lupus</i> , 2020, 29, 389-397.	0.8	22
272	Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. <i>Nature Reviews Neurology</i> , 2020, 16, 154-170.	4.9	65
273	Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102027.	0.9	11
275	Massive activity of cytotoxic cells during refractory Neuromyelitis Optica spectrum disorder. <i>Journal of Neuroimmunology</i> , 2020, 340, 577148.	1.1	5
276	The clinical profile of NMOSD in Australia and New Zealand. <i>Journal of Neurology</i> , 2020, 267, 1431-1443.	1.8	17
277	Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Neurology</i> , The, 2020, 19, 391-401.	4.9	183
278	Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	3.1	46

#	ARTICLE	IF	CITATIONS
279	The nervous system in systemic lupus erythematosus. , 2021, , 469-478.		0
280	Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy. Journal of Neuroradiology, 2021, 48, 28-36.	0.6	24
281	Single-cell approaches to investigate B cells and antibodies in autoimmune neurological disorders. Cellular and Molecular Immunology, 2021, 18, 294-306.	4.8	10
282	Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Neurodegenerative Disease Management, 2021, 11, 49-59.	1.2	16
283	Neuromyelitis optica spectrum disorders. Journal of the Neurological Sciences, 2021, 420, 117225.	0.3	29
284	Type I interferon-activated microglia are critical for neuromyelitis optica pathology. Glia, 2021, 69, 943-953.	2.5	11
285	Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders. BioDrugs, 2021, 35, 7-17.	2.2	11
287	Use of therapeutic plasma exchange for pediatric neurological diseases. Journal of Clinical Apheresis, 2021, 36, 161-176.	0.7	2
289	Rehabilitation in Devic's Syndrome. Case Report. Acta Balneologica, 2021, 63, 78-83.	0.1	0
290	Atypical optic neuritis: An overview. Indian Journal of Ophthalmology, 2021, 69, 27.	0.5	10
291	Monoclonal Antibodies as Neurological Therapeutics. Pharmaceuticals, 2021, 14, 92.	1.7	35
293	Relapse After Cessation of Immunosuppressants in Seropositive Neuromyelitis Optica Spectrum		

#	ARTICLE	IF	CITATIONS
301	Neuromyelitis Optica Spectrum Disorder Treatment—Current and Future Prospects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2801.	1.8	13
302	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. <i>Annals of Neurology</i> , 2021, 89, 895-910.	2.8	72
303	Neuritis Óptica bilateral anti-MOG en un paciente trasplantado renal. <i>Neurology Perspectives</i> , 2021, 1, 133-133.	0.2	0
305	Accelerating clinical research in neuromyelitis optica spectrum disorders. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 89-91.	0.5	3
306	MOG-IgG Associated Disease (MOG-AD) in Adults. <i>Current Treatment Options in Neurology</i> , 2021, 23, 1.	0.7	1
307	Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102750.	0.9	20
309	Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics. <i>Neurotherapeutics</i> , 2021, 18, 1623-1636.	2.1	2
310	The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: Experience with 461 cases from a single centre in South China. <i>Journal of Neuroimmunology</i> , 2021, 353, 577506.	1.1	3
311	AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110068.	0.5	6
312	Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102869.	0.9	16
313	Serum Homocysteine Level Is a Predictor of Relapse and Prognosis in Patients With First-Attack Neuromyelitis Optica Spectrum Disorders. <i>Frontiers in Neurology</i> , 2021, 12, 667651.	1.1	5
314	Efficacy of Low-Dose Rituximab on Neuromyelitis Optica-Associated Optic Neuritis. <i>Frontiers in Neurology</i> , 2021, 12, 637932.	1.1	3
316	Clinical experience of plasmapheresis for neuromyelitis optica patients in Mexico. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 103022.	0.9	4
317	Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: a Meta-analysis of Randomized Control Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 652759.	1.6	7
318	Visual outcome of aquaporin-4 antibody-positive optic neuritis with maintenance therapy. <i>Japanese Journal of Ophthalmology</i> , 2021, 65, 699-703.	0.9	0
319	Optical Coherence Tomography Reveals Longitudinal Changes in Retinal Damage Under Different Treatments for Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Neurology</i> , 2021, 12, 669567.	1.1	6
320	Incidence and prevalence of neuromyelitis optica spectrum disorders in Slovakia. <i>Neurological Research</i> , 2022, 44, 38-46.	0.6	3
321	Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study. <i>Frontiers in Immunology</i> , 2021, 12, 720907.	2.2	6

#	ARTICLE	IF	CITATIONS
322	At this Junction. Survey of Ophthalmology, 2021, , .	1.7	0
323	Treatment of Neuromyelitis Optica Spectrum Disorders. International Journal of Molecular Sciences, 2021, 22, 8638.	1.8	29
324	Clinical risk factors and prognostic model for idiopathic inflammatory demyelinating diseases after haploidentical hematopoietic stem cell transplantation in patients with hematological malignancies. American Journal of Hematology, 2021, 96, 1407-1419.	2.0	5
325	Simultaneous new onset of neuromyelitis optica spectrum disorder in identical twins. BMJ Neurology Open, 2021, 3, e000174.	0.7	1
326	Imaging findings and diagnosis of atypical aggressive demyelinating lesions of the central nervous system. Journal of Radiological Review, 2021, 8, .	0.1	0
327	Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis. Neurology: Neuroimmunology and Neuroinflammation, 2021, 8, .	3.1	60
328	Neuromyelitis optica spectrum disorders: A nationwide Portuguese clinical epidemiological study. Multiple Sclerosis and Related Disorders, 2021, 56, 103258.	0.9	7
329	Pruritus as an initial symptom of neuromyelitis optica spectrum disorder. A peruvian case report. Neuroimmunology Reports, 2021, 1, 100021.	0.2	0
330	Clinical Approach to Autoimmune and Inflammatory Ophthalmologic Disease. , 2021, , 447-467.		0
332	Longitudinally Extensive Transverse Myelitis in a Lupus. Neuromyelitis Optica Overlap. Rambam Maimonides Medical Journal, 2021, 12, e0006.	0.4	6
333	Age-Related Clinical Presentation of MOG-IgG Seropositivity in Israel. Frontiers in Neurology, 2020, 11, 612304.	1.1	11
334	Demyelinating Diseases of the CNS (Brain and Spine). IDKD Springer Series, 2020, , 165-176.	0.8	7
336	Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials. Multiple Sclerosis and Related Disorders, 2020, 43, 102166.	0.9	25
337	MRI Characteristics of NMO, MOG and MS Related Optic Neuritis. Seminars in Ophthalmology, 2020, 35, 333-342.	0.8	25
338	Targeting B cells to modify MS, NMOSD, and MOGAD. Neurology: Neuroimmunology and Neuroinflammation, 2021, 8, .	3.1	30
339	Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life. PLoS ONE, 2017, 12, e0177230.	1.1	34
342	Retinal Optical Coherence Tomography in Neurodegenerative Diseases (Review). Sovremennyye Tehnologii V Medicine, 2015, 7, 116-123.	0.4	11
343	Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy. Current Neuropharmacology, 2020, 19, 220-232.	1.4	24

#	ARTICLE	IF	CITATIONS
344	A diagnostic challenge in a young woman with intractable hiccups and vomiting: a case of neuromyelitis optica. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2015, 5, 28850.	0.4	7
345	New progress in the treatment of neuromyelitis optica spectrum disorder with monoclonal antibodies (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 148.	0.8	5
346	Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence. <i>Journal of Research in Medical Sciences</i> , 2017, 22, 18.	0.4	39
347	Diagnostic modalities in multiple sclerosis: Perspectives in children. <i>Biomedical Journal</i> , 2014, 37, 50.	1.4	11
348	Comprehensive review of neuromyelitis optica and clinical characteristics of neuromyelitis optica patients in Puerto Rico. , 2018, 9, 242.		16
349	Concomitant abducens and facial nerve palsies: A rare presentation in anti-aquaporin-4 antibody-positive neuromyelitis optica. <i>Taiwan Journal of Ophthalmology</i> , 2020, 10, 235.	0.3	1
350	Specificity of Lower Urinary Tract Symptoms in Neuromyelitis Optica in Comparison With Multiple Sclerosis Patients. <i>International Neurourology Journal</i> , 2018, 22, 185-191.	0.5	5
351	Rituximab in neuromyelitis optica: A review of literature. <i>World Journal of Neurology</i> , 2015, 5, 39.	0.6	9
352	Infusion-Related, Short-term, and Delayed Side Effects of Rituximab in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. <i>Shiraz E Medical Journal</i> , 2020, 22, .	0.1	2
353	Unrecognized neuromyelitis optica spectrum disorder with pontine and corpus callosum microhemorrhage. <i>Vojnosanitetski Pregled</i> , 2022, 79, 1270-1273.	0.1	0
355	The Role of Plasma Exchange in the Treatment of Refractory Autoimmune Neurological Diseases: a Narrative Review. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 806-817.	2.1	13
356	Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Immunology</i> , 2021, 12, 660230.	2.2	10
357	Health Disparities, Inequities, and Social Determinants of Health in Multiple Sclerosis and Related Disorders in the US. <i>JAMA Neurology</i> , 2021, 78, 1515.	4.5	68
358	Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103352.	0.9	19
359	Uncommon inflammatory/immune-related myelopathies. <i>Journal of Neuroimmunology</i> , 2021, 361, 577750.	1.1	4
361	Autoimmunerkrankungen. , 2015, , 577-607.		0
362	Infectious and Inflammatory Diseases of the Spine in Children. , 2015, , 1-55.		0
363	Immunohistochemistry. , 2015, , 143-158.		1

#	ARTICLE	IF	CITATIONS
364	Multiple Sklerose und andere immunvermittelte Enzephalopathien. Springer-Lehrbuch, 2016, , 559-585.	0.1	1
365	Optic Neuritis in Children. , 2016, , 427-438.		0
366	Neuromyelitis Optica (Devic's Disease): A New Concept for an Old Disease. , 2016, , 351-359.		0
367	Recurrent Optical Neuritis and Systemic Lupus Erythematosus in a case of benign form of Neuromyelitis Optica Spectrum Disorder. International Journal of Clinical Neurosciences and Mental Health, 2016, 3, .	0.7	0
368	NMO-Spektrum-Erkrankungen (NMOSE). , 2017, , 1-15.		0
369	Infectious, Autoimmune and Other Immune-Mediated Causes of Myelitis. , 2017, , 123-160.		1
371	Anti MOG Antibody Seropositive Neuromyelitis Optica: A Rare Pediatric Case. Noropsikiyatri Arsivi, 2018, 57, 257-260.	0.2	0
372	Prevalence and Pattern of Craniofacial Pain and Headache in Danish Patients with Neuromyelitis Optica Spectrum Disorder. European Neurological Review, 2018, 13, 44.	0.5	1
373	D'ficit moteur et douleur pluriradiculaire faisant d'couvrir une maladie de Devic. Annales Francaises De Medecine D'Urgence, 2018, 8, 239-240.	0.0	0
374	Multiple Sklerose: Therapie. Springer Reference Medizin, 2019, , 1-25.	0.0	0
375	Urine Is an Ideal Biomarker Resource in Early Detecting Neurodegenerative Diseases. , 2019, , 119-134.		0
376	Clinical features of the patients with Neuromyelitis Optica Spectrum Disorder. Noropsikiyatri Arsivi, 2019, 58, 21-25.	0.2	1
377	Systemic lupus erythematosus with the development of neuromyelitis optica (Devic's syndrome) is a rare combination of autoimmune diseases. Sovremennaya Revmatologiya, 2019, 13, 89-95.	0.1	1
378	Paediatric Neuro-Ophthalmology. Current Practices in Ophthalmology, 2020, , 103-117.	0.1	0
379	Neuromyelitis Optica Spectrum Disorder: A Case Report of Effective Combination Immunosuppressant, Corticosteroids, and Therapeutic Plasma Exchange. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 3433-3436.	0.1	2
380	The neuromyelitis optica spectrum disorders. Neurologie Pro Praxi, 2019, 20, 368-372.	0.0	0
381	Overview of the Current Situation and Challenges about Neuromyelitis Optica Spectrum Disorders in the Republic of Macedonia. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 40-46.	0.1	0
382	Neuromyelitis optica spectrum disorder: an overview. Acta Neurobiologiae Experimentalis, 2020, 80, 256-272.	0.4	4

#	ARTICLE	IF	CITATIONS
383	Multiple Sklerose: Therapie. Springer Reference Medizin, 2020, , 1099-1123.	0.0	0
384	Neuromyelitis optica spectrum disorder with negative aquaporin-4 antibodies and positive anti-myelin oligodendrocyte glycoprotein antibodies: A case report. Medical Journal Armed Forces India, 2022, 78, S303-S307.	0.3	0
385	NMO-Spektrum-Erkrankungen (NMOSE). Springer Reference Medizin, 2020, , 1125-1138.	0.0	0
386	Evaluation of glucose-6-phosphate dehydrogenase serum level in patients with multiple sclerosis and neuromyelitis optica. Current Journal of Neurology, 0, , .	0.0	0
387	Isolated Area Postrema Syndrome Presenting as Intractable Nausea and Vomiting. Cureus, 2020, 12, e7058.	0.2	2
388	Current Recommendations on Optic Neuritis. Klinische Monatsblätter Fur Augenheilkunde, 2020, 237, 1286-1289.	0.3	0
389	Acute Transverse Myelitis in Children, Literature Review. Iranian Journal of Child Neurology, 2018, 12, 7-16.	0.2	8
390	The pathologic and diagnostic in magnetic resonance imaging of brain and cervical spine of patients with neuromyelitis optica spectrum disorder. Iranian Journal of Neurology, 2018, 17, 58-63.	0.5	1
391	Evaluation of glucose-6-phosphate dehydrogenase serum level in patients with multiple sclerosis and neuromyelitis optica. Iranian Journal of Neurology, 2019, 18, 150-153.	0.5	1
392	Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder. Neurology and Therapy, 2022, 11, 123-135.	1.4	21
393	Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease. Journal of Neurology, 2022, 269, 3136-3146.	1.8	12
394	Response to treatment in NMOSD: the Australasian experience. Multiple Sclerosis and Related Disorders, 2021, 58, 103408.	0.9	0
395	Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110567.	1.5	8
396	Optical coherence tomography angiography (OCTA) in differential diagnosis of aquaporin-4 antibody seronegative NMOSD and multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 58, 103503.	0.9	6
397	Multidisciplinary Rehabilitation of a Patient With Neuromyelitis Optica. Function and Disability Journal, 2020, 3, 69-76.	0.2	0
398	Vision Prognosis and Associated Factors of Optic Neuritis in Dependence of Glial Autoimmune Antibodies. American Journal of Ophthalmology, 2022, 239, 11-25.	1.7	7
399	Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease. Neurology, 2022, 98, .	1.5	14
400	Possibilities of therapy for neuromyelitis optica spectrum disorders. Russkii Zhurnal Detskoi Nevrologii, 2022, 16, 49-58.	0.1	0

#	ARTICLE	IF	CITATIONS
401	Serum molecular biomarkers in neuromyelitis optica and multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103527.	0.9	3
402	Incidence and risk factors for venous thromboembolism during an acute attack in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103513.	0.9	2
403	Effective connectivity within the corticothalamic circuit in the neuromyelitis optica patients: A comparative study using resting-state fMRI. <i>Journal of Clinical Neuroscience</i> , 2022, 97, 25-31.	0.8	0
404	Potential therapeutic strategies in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Autoimmunity Reviews</i> , 2022, 21, 103032.	2.5	1
405	Comparison of clinical and radiological features of aquaporin4 (AQP-4) antibody positive neuromyelitis optica spectrum disorder (NMOSD) and anti myelin oligodendrocyte glycoprotein (Anti-MOG) syndrome-our experience from Northwest India. <i>Annals of Indian Academy of Neurology</i> , 2022, .	0.2	2
406	Centrally-located transverse myelitis would facilitate the differentiation of NMOSD and MOG-AD from MS. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103664.	0.9	2
407	Emerging drugs for the acute treatment of relapses in adult neuromyelitis optica spectrum disorder patients. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 91-98.	1.0	6
409	Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. <i>Journal of Neuroinflammation</i> , 2022, 19, 62.	3.1	30
410	Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD. <i>Neurotherapeutics</i> , 2022, 19, 808-822.	2.1	14
411	Efficacy of monoclonal antibodies in neuromyelitis optica: An updated systematic review with meta-analysis. <i>Clinical and Experimental Neuroimmunology</i> , 2022, 13, 194-207.	0.5	0
412	Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103730.	0.9	11
413	Prevalence and direct costs of patients with neuromyelitis optica: data from Campania region in southern Italy. <i>Future Rare Diseases</i> , 2021, 1, .	0.1	3
414	Evaluating the Economic Burden of Relapses in Neuromyelitis Optica Spectrum Disorder: A Real-World Analysis Using German Claims Data. <i>Neurology and Therapy</i> , 2022, 11, 247-263.	1.4	11
415	Pediatric Neuromyelitis Optica Spectrum Disorder: Case Series and Literature Review. <i>Life</i> , 2022, 12, 19.	1.1	3
416	White matter microglia heterogeneity in the CNS. <i>Acta Neuropathologica</i> , 2022, 143, 125-141.	3.9	48
417	Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 981-991.	1.9	15
422	Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore. <i>Asia-Pacific Journal of Ophthalmology</i> , 2022, 11, 184-195.	1.3	4
423	Clinical Characteristics and Outcomes of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder With Brainstem Lesions as Heraldng Prodrome. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	1

#	ARTICLE	IF	CITATIONS
424	Optic neuritis with potential for poor outcome. Practical Neurology, 2022, , practneurol-2021-003228.	0.5	0
425	Efficacy and safety of monoclonal antibodies in neuromyelitis optica spectrum disorders: A survival meta-analysis of randomized controlled trials. Advances in Ophthalmology Practice and Research, 2022, , 100064.	0.3	0
426	Neuromyelitis optica spectrum disorder: do patients positive and negative for anti-aquaporin-4 antibodies present distinct entities? A Colombian perspective. Neurología (English Edition), 2022, , .	0.2	0
428	Disease Course and Outcomes in Patients With the Limited Form of Neuromyelitis Optica Spectrum Disorders and Negative AQP4-IgG Serology at Disease Onset: A Prospective Cohort Study. Journal of		

#	ARTICLE	IF	CITATIONS
443	Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review. <i>Expert Review of Clinical Immunology</i> , 2023, 19, 71-91.	1.3	6
444	Neuromyelitis optica: Clinical course and potential prognostic indicators. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 69, 104414.	0.9	3
446	Relevance of bright spotty lesions in neuromyelitis optica spectrum disorders (NMOSD): a case series. <i>Egyptian Journal of Neurology, Psychiatry and Neurosurgery</i> , 2022, 58, .	0.4	1
447	Berlin Registry of Neuroimmunological entities (BERLimmun): protocol of a prospective observational study. <i>BMC Neurology</i> , 2022, 22, .	0.8	0
448	Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder. <i>Neurology</i> , 0, , 10.1212/WNL.0000000000201625.	1.5	1
449	Neuromyelitis-optica-Spektrum-Erkrankung: Pathogene Antikörper als Auslöser und Angriffspunkt. , 0, , .		0
450	Consensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapy. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2022, 14, 139-148.	0.2	4
451	Neuromyelitis optica spectrum disorder: pathophysiological approach. <i>International Journal of Neuroscience</i> , 0, , 1-13.	0.8	1
452	Therapeutic strategies in NMOSD and MOGAD patients: A multicenter cohort study in Latin America. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 71, 104508.	0.9	0
453	Dávic-Syndrom (Neuromyelitis optica). <i>Springer Reference Medizin</i> , 2023, , 1-3.	0.0	0
454	A RARE CASE NEUROMYELITIS OPTICA SPECTRUM DISORDER. , 2022, , 86-87.		0
455	Systemic lupus erythematosus with acute ischemic optic neuropathy complicated with neuromyelitis optica: a case report. <i>Journal of Medical Case Reports</i> , 2023, 17, .	0.4	1
456	Immunoabsorption as maintenance therapy for refractory neuromyelitis optica spectrum disorder. <i>Therapeutic Advances in Neurological Disorders</i> , 2023, 16, 175628642211503.	1.5	2
457	Understanding Treatment Decisions in Neuromyelitis Optica Spectrum Disorder: A Global Clinical Record Review with Patient Interviews. <i>Neurology and Therapy</i> , 2023, 12, 619-633.	1.4	3
458	The Acute Optic Neuritis Network (ACON): Study protocol of a non-interventional prospective multicenter study on diagnosis and treatment of acute optic neuritis. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	4
459	Characterization of Disease Severity and Stability in NMOSD: A Global Clinical Record Review with Patient Interviews. <i>Neurology and Therapy</i> , 2023, 12, 635-650.	1.4	3
460	Aquaporin-4 Antibody Dynamics and Relapse Risk in Seropositive Neuromyelitis Optica Spectrum Disorder Treated with Immunosuppressants. <i>Annals of Neurology</i> , 2023, 93, 1069-1081.	2.8	4
462	The neuro-ophthalmological manifestations of NMOSD and MOGAD—a comprehensive review. <i>Eye</i> , 2023, 37, 2391-2398.	1.1	3

#	ARTICLE	IF	CITATIONS
463	Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder. CNS Drugs, 2023, 37, 363-370.	2.7	3
464	Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)“ revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. Journal of Neurology, 2023, 270, 3341-3368.	1.8	23
465	Plasma exchange in inflammatory demyelinating disorders of the central nervous system: reasonable use in the clinical practice. Arquivos De Neuro-Psiquiatria, 2023, 81, 296-307.	0.3	3
472	Rare autoimmune and autoinflammatory neurologic disorders. , 2023, , 189-219.		0
478	Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) “ revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. Journal of Neurology, 2024, 271, 141-176.	1.8	6
481	Breastfeeding in Immune-Mediated Demyelinating Disorders of the Central Nervous System. , 2023, , 299-314.		0
482	Clinical efficacy of anti-CD20 antibodies in neurological and neuromuscular diseases. , 2024, , 375-400.		0
485	Understanding Nontraumatic Spinal Cord Disorders. , 2023, , 307-340.		0
494	Demyelinating Diseases of the CNS (Brain and Spine). IDKD Springer Series, 2024, , 189-202.	0.8	0